EULAR/ACR系统性红斑狼疮分类标准
EULAR与ACR联合项目制定了新的SLE分类标准,以ANA阳性为入围标准,采用加权条目计分,总分≥10可分类为SLE。验证数据显示新标准特异性93%、敏感性96%,在保持ACR标准高特异性的同时接近SLICC 2012标准的敏感性。
要点
- 以ANA阳性为入围标准,加权条目计分,总分≥10分类为SLE
- III/IV型狼疮肾炎单项即达10分,可单独满足分类标准
- 验证数据:特异性93%、敏感性96%(SLICC敏感性97%)
核心结论
- 新EULAR/ACR分类标准在保持ACR标准高特异性(93%)的同时,敏感性达96%,接近SLICC 2012标准的97%。
研究设计与样本
- 由EULAR和ACR共同支持的大型跨大西洋、多阶段全球性项目,旨在制定SLE新分类标准。
主要发现
- 验证数据显示新标准特异性93%(与ACR标准相同),敏感性96%(SLICC标准为97%)。
- 新标准以ANA阳性为入围标准,条目加权计分从2分(谵妄、非感染性发热、抗磷脂抗体)到10分(III或IV型狼疮肾炎)。
- 分类截断值为10分,仅III/IV型狼疮肾炎一项即可达到10分。
- 条目按域组织,同一域内仅计入最高条目分值。
- 统一规则:仅当无更可能的替代诊断时,条目才归因于SLE并计分。
关键数值与推荐
- 入围标准:ANA阳性。
- 加权条目分值范围:2分(谵妄、非感染性发热、抗磷脂抗体)至10分(III或IV型狼疮肾炎)。
- 分类截断值:总分≥10分。
- 验证数据:特异性93%,敏感性96%(SLICC 2012标准敏感性97%)。
临床怎么用
- 临床可依据ANA阳性入围后按域计分,总分≥10分且无更可能替代诊断时分类为SLE。
- III/IV型狼疮肾炎单项即满足分类标准,无需其他条目。
- 同一域内仅计最高分值条目,避免重复计分。
局限性
- 原文指出新标准尚需在其他队列中进行外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Supported by both the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) from the beginning, a large transatlantic, and in many phases worldwide, project has led to new classification criteria for systemic lupus erythematosus (SLE). The project had ambitious goals, particularly maintaining the high specificity of the ACR criteria, while reaching a sensitivity close to the Systemic Lupus International Collaborating Clinics (SLICC) 2012 criteria. The validation data suggest that the new criteria reached this goal, with a specificity of 93% (as for the ACR criteria) and a sensitivity of 96% (vs 97% for the SLICC criteria). The new EULAR/ACR classification criteria use positive antinuclear antibodies (ANA) as an entry criterion and have weighted items, ranging from 2 (for delirium, non-infectious fever and anti-phospholipid antibodies) to 10 (for class III or IV lupus nephritis). The cut-off for classification is 10, reached by class III/IV nephritis alone. Items are organized in domains, within which only the highest item is to be counted. Instead of many defined exclusions, one rule is used for all, namely that items are to be attributed to SLE and counted only if there is no more likely alternative diagnosis. These criteria are now expected to be externally validated in various other cohorts. The team spirit and collegiality characteristic for this EULAR/ACR criteria effort will hopefully facilitate future international projects on SLE.
引用
- Aringer M. EULAR/ACR classification criteria for SLE. Semin Arthritis Rheum. 2019. PMID: 31779843. doi:10.1016/j.semarthrit.2019.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。